BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Express Scripts
US Army
Boehringer Ingelheim
US Department of Justice
Julphar
Cantor Fitzgerald
McKinsey
Moodys
Novartis

Generated: January 23, 2018

DrugPatentWatch Database Preview

SOMAVERT Drug Profile

« Back to Dashboard

When do Somavert patents expire, and when can generic versions of Somavert launch?

Somavert is a drug marketed by Pharmacia And Upjohn and is included in one NDA. There is one patent protecting this drug.

This drug has fifty-four patent family members in fifteen countries.

The generic ingredient in SOMAVERT is pegvisomant. One supplier is listed for this compound. Additional details are available on the pegvisomant profile page.
Summary for SOMAVERT
International Patents:54
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 15
Drug Prices:see details
DailyMed Link:SOMAVERT at DailyMed
Drug patent expirations by year for SOMAVERT

US Patents and Regulatory Information for SOMAVERT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-001 Mar 25, 2003 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-004 Jul 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-003 Mar 25, 2003 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-005 Jul 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for SOMAVERT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-005 Jul 31, 2014 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-003 Mar 25, 2003 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-001 Mar 25, 2003 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-005 Jul 31, 2014 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-003 Mar 25, 2003 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-004 Jul 31, 2014 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-003 Mar 25, 2003 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for SOMAVERT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,637,646 Growth hormone variants ➤ Subscribe
6,004,931 Method for inhibiting growth hormone action ➤ Subscribe
6,057,292 Method for inhibiting growth hormone action ➤ Subscribe
5,854,026 Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1 ➤ Subscribe
5,534,617 Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 ➤ Subscribe
6,780,613 Growth hormone variants ➤ Subscribe
6,040,136 Enrichment method for variant proteins with altered binding properties ➤ Subscribe
6,428,954 Method for identifying active domains and amino acid residues in polypeptides and hormone variants ➤ Subscribe
5,834,250 Method for identifying active domains and amino acid residues in polypeptides and hormone variants ➤ Subscribe
6,136,563 Human growth hormone variants comprising amino acid substitutions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for SOMAVERT

Supplementary Protection Certificates for SOMAVERT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0210 Netherlands ➤ Subscribe 300210, 20160920, EXPIRES: 20171112
C/GB05/047 United Kingdom ➤ Subscribe PRODUCT NAME: PEGVISOMANT, OPTIONALLY IN THE FORM OF A PEGYLATION VARIANT; REGISTRATION NO/DATE: EU/1/02/240/001 - 003 20021113
0851925/01 Switzerland ➤ Subscribe FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
C0043 France ➤ Subscribe PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113
2005 00043 Denmark ➤ Subscribe
8 Finland ➤ Subscribe
204 Luxembourg ➤ Subscribe 91204, EXPIRES: 20171113
C029/2005 Ireland ➤ Subscribe SPC029/2005: 20061023, EXPIRES: 20171112
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Boehringer Ingelheim
Express Scripts
Argus Health
Teva
Covington
Baxter
Daiichi Sankyo
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot